Inhalation Sciences AB signs new distribution agreement to cover China, Hong Kong and Macau
(Stockholm, Sverige, 12 April 2022) Inhalation Sciences AB has signed a new distribution with Quantaflux Industrial Co. Ltd that will cover the crucial China, Hong Kong and Macau markets. CEO Manoush Masarrat: “China is an important market for inhaled medicine, with robust R&D and a high level of local investment. We are delighted to be partnering With Quantaflux Industrial.”
Quantaflux Industrial Co. Ltd is a Labtech distributor for lab testing instruments covering China, Hong Kong and Macau. The company has strong ties to China’s extensive network of inhalation drug R&D labs as a distributor of instruments for inhaler testing.
ISAB represents a positive complement for Quantaflux’s portfolio, enabling the company to expand its current offering beyond inhaler delivery devices and into substance and drug development studies - through ISAB’s range of novel instruments for precision performance in preclinical PK (Pharmacokinetics) studies.
Ruty Li, General Manager of Quantaflux Industrial: “We are very glad to be the distributor of ISAB, an innovator in preclinical in vitro and in vivo PK tests. We hope we can contribute to the development of the Chinese OINDP (Orally Inhaled and Nasal Drug Products) market with the flagship products of ISAB and our support.”
ISAB CEO Manoush Masarrat: “China is a key market for inhalation drug development and inhaled generics companies with a robust R&D sector and a high level of local investment. We look forward to partnering with Quantaflux Industries and expanding our customer base in these crucial markets.”
For more information about Inhalation Sciences, please contact:
Manoush Masarrat, CEO
E-mail: Manoush.masarrat@inhalation.se
About Inhalation Sciences Sweden AB (publ)
Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company’s patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.
Tags: